Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NexGel Inc ( (NXGL) ) has shared an announcement.
On July 14, 2025, NEXGEL, Inc. announced the expansion of its partnership with STADA Arzneimittel AG, a European leader in consumer health, to launch digestive enzyme formulas and solutions for scars and stretch marks in North America. As part of the agreement, STADA will provide $1 million in non-dilutive capital to support the product launches and marketing efforts, reflecting a shared vision to bring these health solutions to North American consumers.
The most recent analyst rating on (NXGL) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.
Spark’s Take on NXGL Stock
According to Spark, TipRanks’ AI Analyst, NXGL is a Neutral.
The overall score is influenced primarily by financial performance and technical analysis. Strong revenue growth and positive earnings call sentiment are overshadowed by persistent financial losses and negative cash flow. The moderate technical indicators provide some support but are insufficient to offset valuation concerns.
To see Spark’s full report on NXGL stock, click here.
More about NexGel Inc
NEXGEL, Inc., based in Langhorne, Pa., is a leading provider of healthcare, beauty, and over-the-counter products, specializing in ultra-gentle, high-water-content hydrogels. The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades and offers brands such as SilverSeal®, Hexagels®, Turfguard®, Kenkoderm®, and Silly George®. NEXGEL also maintains strategic contract manufacturing relationships with leading consumer healthcare companies.
Average Trading Volume: 35,370
Technical Sentiment Signal: Buy
Current Market Cap: $27.54M
For detailed information about NXGL stock, go to TipRanks’ Stock Analysis page.